Renexxion Ireland Ltd. and Dr. Falk Pharma GmbH Announce FDA Clearance of the Investigational New Drug Application for Naronapride to Treat Gastroparesis and Subsequent Expansion of the Ongoing Phase 2b MOVE-IT Study to the United States
March 27, 2024 08:30 ET
|
Renexxion LLC
ROSCREA, Ireland and FREIBURG, Germany, March 27, 2024 (GLOBE NEWSWIRE) -- Renexxion Ireland Limited (“Renexxion”), a private biopharmaceutical company committed to delivering innovative drugs to...
Renexxion Ireland’s European Partner, Dr. Falk Pharma GmbH, has Elected PPI-non-responsive Symptomatic GERD as the Second Naronapride Indication to Develop and Commercialize in their Licensed Territories
February 07, 2024 08:00 ET
|
Renexxion LLC
ROSCREA, Ireland, and FREIBURG, Germany, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Renexxion Ireland Limited (“Renexxion”), a private biopharmaceutical company committed to delivering innovative drugs to...
Renexxion to Present at the Oppenheimer 34ᵗʰ Annual Healthcare Life Sciences Conference
February 01, 2024 08:35 ET
|
Renexxion LLC
ROSCREA, Ireland, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Renexxion Ireland Limited (“Renexxion”), a private biopharmaceutical company committed to delivering innovative drugs to patients with high unmet...
Renexxion Ireland Ltd. Announces FDA Clearance of Investigational New Drug (IND) Application for Naronapride to Treat PPI-Non-Responsive Symptomatic GERD
January 24, 2024 07:00 ET
|
Renexxion LLC
ROSCREA, Ireland, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Renexxion Ireland Limited (“Renexxion”), a private biopharmaceutical company committed to delivering innovative drugs to patients with high unmet...
Renexxion Ireland has Completed a Successful Pre-IND Consultation with the United States FDA for Development of Naronapride for Patients with PPI-non-responsive Symptomatic GERD
December 20, 2023 16:11 ET
|
Renexxion LLC
ROSCREA, Ireland, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Renexxion Ireland Limited (“Renexxion”), a private biopharmaceutical company committed to delivering innovative drugs to patients with high unmet...
Renexxion Ireland Announces Issuance of Two U.S. Patents Covering a Novel Crystal Isoform of Naronapride
November 30, 2023 07:00 ET
|
Renexxion LLC
ROSCREA, Ireland, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Renexxion Ireland Limited (“Renexxion”), a private biopharmaceutical company committed to delivering innovative drugs to patients with high unmet...
Renexxion to Present at the Oppenheimer Healthcare Private Company Showcase
October 04, 2023 07:00 ET
|
Renexxion LLC
LOS ALTOS, Calif., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Renexxion LLC (“Renexxion” or the “Company”), a private clinical-stage biopharmaceutical company committed to delivering innovative drugs to...